[HTML][HTML] Strategies to improve outcomes of patients with EGFR-mutant non–small cell lung cancer: review of the literature
C Zhou, L Di Yao - Journal of Thoracic Oncology, 2016 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
[HTML][HTML] Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
L Dong, D Lei, H Zhang - Oncotarget, 2017 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) mutations (EGFRm+) occur in 10–35% of non-
small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase …
small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase …
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
The management of non–small cell lung carcinoma (NSCLC) has been transformed by the
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
C Tomasello, C Baldessari, M Napolitano, G Orsi… - Critical reviews in …, 2018 - Elsevier
In the last few years, the development of targeted therapies for non-small cell lung cancer
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …
[HTML][HTML] Hype or hope–Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant …
F Papini, J Sundaresan, A Leonetti, M Tiseo… - Critical Reviews in …, 2021 - Elsevier
Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer
J Gao, HR Li, C Jin, JH Jiang, JY Ding - Clinical and Translational …, 2019 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) represents a paradigm
shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first …
shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first …
[HTML][HTML] The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non …
M Xu, Y Xie, S Ni, H Liu - Annals of translational medicine, 2015 - ncbi.nlm.nih.gov
First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs),
gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients …
gefitinib and erlotinib, produce reliable responses and survival benefits in selected patients …
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
AB Cortot, PA Jänne - European Respiratory Review, 2014 - Eur Respiratory Soc
The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …
[HTML][HTML] The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the current
recommended option for the first-line treatment of patients with EGFR-mutant non-small cell …
recommended option for the first-line treatment of patients with EGFR-mutant non-small cell …
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …